Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0820 Novartis ofatumumab approval
BioCentury & Getty Images

Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells 

Aug 20, 2020 | 11:40 PM GMT

With FDA’s approval of Kesimpta ofatumumab for multiple sclerosis, Novartis could become the latest company to reap the added benefits of launching a drug with a convenient route of administration

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE